[Clinical experience with FK 506].
FK 506 is a superior immunosuppressive agent that should improve patient survival after the commonly performed transplant procedures, make feasible transplantations that have been previously impractical, allow immune intervention for serious autoimmune diseases, and create a better spin-off understanding of basic biologic processes including signal transduction.
Starzl
T E
TE
Abu-Elmagd
K
K
Fung
J J
JJ
Todo
S
S
Tzakis
A G
AG
McCauley
J
J
Demetris
A J
AJ
D001327:Autoimmune Diseases / Q000188:drug therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy / Q000209:etiology; D016559:Tacrolimus / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D016559:Tacrolimus
Expérience clinique du FK 506.